Abstract Library

#4660 Clinical significance of interval imaging in patients with well-differentiated neuroendocrine neoplasms (NENs) receiving peptide receptor radionuclide therapy (PRRT)

Introduction: PRRT is an effective therapy for advanced NENs with SSTR-avid disease, however, the role of interval imaging in between PRRT cycles and its benefit is unknown.

Conference:

Presenting Author:

Authors: Grewal U, Patel R, Chandasekharan C,

Keywords: Peptide receptor radionuclide therapy, interval imaging, neuroendocrine tumour,

#4498 Quality of life outcome after each cycle in NET patients receiving peptide receptor radionuclide therapy (PRRT)

Introduction: Quality of Life (QoL) Questionnaire GI NET21 was developed specifically for neuroendocrine tumours (NET). A significant proportion of all patients with GEP-NETs will ultimately present with a wide variety of NET-related symptoms such as skin flushing, diarrhoea and pain as well as disease related worries that can reduce QoL. Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to extend survival. However, QoL data post PRRT is still somewhat limited.

Conference:

Presenting Author: Vito I

Authors: Vito I, Santillan N, Davis N, Navalkissoor S,

Keywords: Lu-177-DOTATATE, PRRT, Quality of Life,

#4370 Role of 68GA-DOTATOC pet/ct in therapeutic decision-making for well-differentiated neuroendocrine tumours

Introduction: 68Ga-DOTATOC PET/CT is a highly sensitive and specific test for assessing gastroenteropancreatic and pulmonary neuroendocrine tumours (NET) expressing somatostatin receptors.

Conference:

Presenting Author: Cruz-Diaz W

Authors: Cruz Diaz W, Landaeta Kancev L, Martinez-Amores Martínez B, Bastidas Tamayo J, Estrella Santos A,

Keywords: 68Ga-DOTATOC PET/CT, well-differentiated, gastroenteropancreatic, pulmonary, neuroendocrine tumour, Lu-177-DOTATATE,

#4290 TB-161-Dotatate and Lu-177-Dotatate as a tandem therapy

Introduction: Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express cell-membrane specific peptide receptors, such as somatostatin receptors.

Conference:

Presenting Author:

Authors: Hambapersad T, Maharaj M,

Keywords: TB-161-Dotatate, Lu-177-Dotatate, Tandem,

#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)

Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Suh M, Cheon G, Lee D,

Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,